Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences -- Ignore unavailable to you. Want to Upgrade?

To: hentied who wrote (1866)	4/20/2016 12:02:11 PM
From: mokelumne river	Read Replies (1) \| Respond to of 2026

I am going to suggest that the asset that Denner wanted to control was Fispemifene, and thus his interest in Repros (Androxal). Seems that Denner (like Pascoe with us riding along) lost the bet on Fispemifine and Androxal. So we (and Denner) are back down to the asset that Apricus was founded upon, Vitaros. At this point I would think that Denner would let things play out with Vitaros. To Pascoe's credit, he negotiated getting US rights back and may have a path through the FDA. I should note that Pascoe's only expert in dealing with the FDA is Troupin who is leaving at the end of May. That is a little concerning to me. Back to your point Hentied, I would be more worried if Denner were an Icahn clone. I don't think that Denner has the same gut and strip mentality as his former mentor has. But we will see.

To: hentied who wrote (1866)	4/20/2016 1:04:01 PM
From: Mirror Image	Respond to of 2026

If Denner bought out the existing notes, which I would assume would be available at a huge discount. He could then not renew the notes force the company into bankruptcy and walk away with the assets, leaving the stockholders with nihil. Just saying it is possible. Really? And why would notes for $9 M + that are backed by the totality of the companies assets be available at a HUGE discount? Does the Company not have money to pay the monthly installments + interest? Does the Company not have a recurring royalty? Does the Company not have the means to raise $9 M + ? Does the Company not have any value that would impede them to issue shares to raise cash when it came to that? And lastly, when do the terms in a contractual agreement change if you are not in default? If he buys the notes, he cannot change the terms unless Apricus is in default. If we were talking about $50M or $100 M in debt.. Then YES. I would entertain the possibility of this happening. But we are talking about $9M and we are talking about a company that has a drug in the market that generates royalties and hopefully soon Sales Milestones payments. Not 4 months ago they raised $10M by issuing shares @ .88. What impedes them from issuing shares at a higher discount? Hmm. No, that's right. They would allow the company to go into bankruptcy and lose it completely before they issue more shares. That makes sense.